Tg Therapeutics (TGTX) Non-Current Deferred Tax Liability (2022 - 2024)

Tg Therapeutics' Non-Current Deferred Tax Liability history runs 3 years deep, the most recent figure standing at $6.2 million for Q4 2024.

• On a quarterly basis, Non-Current Deferred Tax Liability fell 89.97% year-over-year to $6.2 million in Q4 2024; TTM through Dec 2024 was $6.2 million, a 89.97% decrease from a year earlier, with the FY2024 full-year figure at $6.2 million, down 89.97% from the prior year.
• Non-Current Deferred Tax Liability retreated to $6.2 million in Q4 2024 per TGTX's latest filing, from $61.8 million in the prior quarter.
• Across five years, Non-Current Deferred Tax Liability topped out at $61.8 million in Q4 2023 and bottomed at $6.2 million in Q4 2024.
• The 3-year median for Non-Current Deferred Tax Liability is $38.5 million (2022), against an average of $35.5 million.
• Across the five-year window, Non-Current Deferred Tax Liability jumped 60.52% in 2023 and tumbled 89.97% in 2024, its largest moves.
• Year by year, Non-Current Deferred Tax Liability stood at $38.5 million in 2022, then soared by 60.52% to $61.8 million in 2023, then tumbled by 89.97% to $6.2 million in 2024.
• Per Business Quant, the three latest TGTX Non-Current Deferred Tax Liability figures stand at $6.2 million (Q4 2024), $61.8 million (Q4 2023), and $38.5 million (Q4 2022).